Clinical trial · Observational
D2 Versus D1 Gastrectomy of Operable Gastric Cancer
Operative and Long Term Oncological Outcomes After D2 Versus D1 Gastrectomy of Operable Gastric Cancer
NCT04429841CI-TRIAL-00045522completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Surgery is the mainstay treatment of operable gastric carcinoma but the optimal extent of lymph node (LN) dissection is controversial. The aim of this observational study is to assess the outcomes after curative D2 compared to D1 gastrectomy of operable gastric carcinoma regarding operative and long term oncological outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radical gastrectomy with D1 lymphadenectomy | Procedure | — | UNRESOLVED |
| Radical gastrectomy with D2 lymphadenectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- D1 Gastrectomy
- description
- Patients are managed by radical gastrectomy with D1 lymphadenectomy
- interventionNames
- Procedure: Radical gastrectomy with D1 lymphadenectomy
- label
- D2 Gastrectomy
- description
- Patients are managed by radical gastrectomy with D2 lymphadenectomy
- interventionNames
- Procedure: Radical gastrectomy with D2 lymphadenectomy
Primary outcomes (2)
- measure
- Postoperative morbidity rate
- timeFrame
- 30 days after surgery
- description
- Frequency of early postoperative complications
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients younger than 80 years with a histologically confirmed operable adenocarcinoma of the stomach with complete follow up after surgery for average 5 years Exclusion Criteria: * Complicated gastric cancer (obstructed or perforated) * Irresectable or metastatic disease * Previous or coexisting cancer * Prior gastric surgery.
References
Publications (2)
- BACKGROUNDTamura S, Takeno A, Miki H. Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol. 2011;2011:748745. doi: 10.1155/2011/748745. Epub 2011 Jun 14. PMID 22312521
- BACKGROUNDHartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004 Jun 1;22(11):2069-77. doi: 10.1200/JCO.2004.08.026. Epub 2004 Apr 13. PMID 15082726